Publications by authors named "S A C Siqueira"
Background: Rhabdomyosarcoma (RMS), a rare malignant tumor, frequently affects pediatric patients, with 35%-40% occurring in the head and neck. This study analyzes the clinicopathologic profile of pediatric head and neck rhabdomyosarcomas from Brazil, Guatemala, Mexico, and South Africa.
Methods: We reviewed 44 cases from 10 Oral and Maxillofacial Pathology services, conducting immunohistochemical analyses of desmin, myogenin, Myo-D1, and Ki67, with quantification via QuPath software.
The investigation of new drugs is slow and costly. Drug repositioning, like with Hydralazine (HDZ), an old antihypertensive, can accelerate the process. HDZ and its hydrazonic derivatives exhibit diverse biological activities, promising for new drugs.
View Article and Find Full Text PDFAmiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.
JAMA Cardiol
December 2024
Importance: Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy.
Objective: To test the hypothesis that ICD is more effective than amiodarone therapy for primary prevention of all-cause mortality in patients with chronic Chagas cardiomyopathy and moderate to high mortality risk, assessed by the Rassi score.
Article Synopsis
- Patients with heart failure and improved ejection fraction (HFimpEF) face significant health risks during hospitalizations, showing higher rates of complicated hospital admissions compared to patients with consistently higher ejection fractions (LVEF >40%).
- In a study involving 6263 patients, those with HFimpEF accounted for 18% and experienced more severe hospital events despite similar lengths of stay and in-hospital mortality rates as patients with stable LVEF.
- The outcomes indicated that 66% of HFimpEF patients experienced a decrease in their LVEF to ≤40%, pointing to potential ongoing heart function decline despite previous improvements.